CommercialCoverageMedium impact
06.02.06s, Genetic Testing for Inherited Breast Cancer 1 (BRCA1) and Breast Cancer 2 (BRCA2) Mutations (Independence Administrators)
Independence Blue Cross·Genetics, Oncology, OB-GYN·Medical Policy
Effective date
Nov 26, 2025
We identified it
Jun 19, 2026
Summary
Independence Administrators reissued their policy on genetic testing for BRCA1 and BRCA2 mutations effective 11/26/2025. This is a recent policy update that may contain new coverage criteria, prior authorization requirements, or billing guidance for hereditary breast cancer genetic testing. The billing team must review the full policy text to identify specific code changes, coverage updates, and any new documentation or authorization requirements.
Action Required
By 11/26/2025: Billing and clinical teams must obtain and review the full policy text from the provided URL (https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=11&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-06-02-06s). Identify all specific CPT codes, HCPCS codes, and ICD-10 codes referenced in the policy. Update billing software, encounter forms, and provider education materials to reflect any new prior authorization requirements, coverage limitations, or documentation requirements for BRCA1/BRCA2 genetic testing. Ensure all staff processing genetic testing claims are trained on the updated policy requirements before the effective date. Flag any conflicts with previous guidance and implement new workflows immediately upon the effective date.